NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 Pipeline Review, H1 2019
Summary
NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 pipeline Target constitutes close to 6 molecules. The latest report NT 3 Growth Factor Receptor Pipeline Review, H1 2019, outlays comprehensive information on the NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 Tropomyosin receptor kinase C TrkC or NT3 growth factor receptor is a protein encoded by the NTRK3 gene. It is involved in nervous system and probably heart development. Upon binding of its ligand neurotrophin3, NTRK3 autophosphorylates and activates different signaling pathways, including the AKT and the MAPK pathways that control cell survival and differentiation. The molecules developed by companies in PreRegistration, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 2 respectively.
Report covers products from therapy areas Oncology, Genetic Disorders and Central Nervous System which include indications NonSmall Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Bile Duct Cancer Cholangiocarcinoma, Breast Cancer, Central Nervous System CNS Tumor, Fibrosarcoma, Neuroblastoma, Papillary Thyroid Cancer, Salivary Gland Cancer, Thyroid Cancer, Alzheimer's Disease, Anaplastic Large Cell Lymphoma ALCL, Astrocytoma, Basal Cell Carcinoma Basal Cell Epithelioma, Biliary Tumor, Brain Tumor, Cervical Cancer, CharcotMarieTooth Disease, Colon Cancer, Gastrointestinal Stromal Tumor GIST, Glioblastoma Multiforme GBM, Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Cancer Renal Cell Cancer, Leptomeningeal Disease Neoplastic Meningitis, Leptomeningeal Carcinomatosis, LettererSiwe Disease Multifocal and multisystemic disseminated Langerhanscell histiocytosis, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Multiple Myeloma Kahler Disease, Neuroendocrine Tumors, NonHodgkin Lymphoma, NonSmall Cell Lung Carcinoma, Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma and Synovial Sarcoma.
Furthermore, this report also reviews key players involved in NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1
The report reviews NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects
The report assesses NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding NT 3 Growth Factor Receptor TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope